Ovcar 5

Human ECFCs were isolated from neonatal cord and peripheral blood and their distinct endothelial phenotypes were verified by flow cytometry as previously described (see Supporting Information Fig. S1) (Hofmann et al., 2009; 2012,; Reinisch and Strunk, 2009 (link, link, link); Reinisch et al., 2009 (link)). HUVECs were obtained from Lonza (Basel, Switzerland). ECFC and HUVECs were grown in endothelial growth medium-2 (EGM-2) (Lonza) containing 2% FBS and 1% penicillin/streptomycin/L-glutamine/heparin (Life Technologies, Carlsbad, CA, USA) and EGM-2 growth factor supplements (composed of bFGF, IGF-2, EGF, VEGF, ascorbic acid, hydrocortisone). Ovarian carcinoma cell lines OVCAR-3 (American Type Culture Collection, Manassas, VA, USA), OVCAR-5 (kindly provided by the Cell Culture Core, Vascular Biology Program, Boston Children's Hospital, Boston, MA, USA) and COV-362 (Sigma Aldrich, St. Louis, MO, USA) were grown in DMEM containing 10% FBS.

Human cervical cancer cell line HeLa, Human ovarian adenocarcinoma cell line OVCAR-5 and Human breast adenocarcinoma cell line MCF-7 were obtained from American Type Culture Collection (ATCC). Human dermal fibroblasts were obtained from the University Hospital Lübeck (UKSH, Lübeck, Germany). HeLa and MCF-7 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM low glucose, Sigma, USA) containing 10% fetal bovine serum (FBS gold, PAA, USA) and 1% Penicillin/Streptomycin (PAA, USA). OVCAR-5 cells were cultured in RPMI-1640 medium (Sigma, USA) containing 10% FBS and 1% Penicillin/Streptomycin. Fibroblast cells were maintained in DMEM medium (High glucose, Sigma, USA) containing 10% FBS and 1% Penicillin/Streptomycin.

The human OC cell line CaOV3 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA), and the OVCAR-5 cell line was obtained from Dr. Thomas Hamilton (Fox Chase Cancer Centre, Philadelphia, PA, USA). Both cell lines were authenticated via a short tandem repeat (STR) DNA profile in 2020. The OVCAR-5 cells were grown in RPMI 1640 media (Sigma Aldrich, St. Louis, MO, USA). Recent reports have indicated that OVAR-5 might originate from metastatic gastrointestinal cancer, and were potentially wrongfully labelled as being ovarian cancer [26 (link)]. CaOV3 cells were grown in DMEM media (Sigma Aldrich, St. Louis, MO, USA). Both cell lines were cultured with the addition of 10% foetal bovine serum (Bovogen Biologicals, East Keilor, VIC, Australia) supplemented with 1% penicillin/streptomycin (Sigma Aldrich, St. Louis, MO, USA) and 1% L-glutamine (Sigma Aldrich, St. Louis, MO, USA). OVCAR-5 and CaOV3 cells were made resistant to CBP after treatment with 6–8 cycles of CBP (50 μM, Hospira Australia, Pty Ltd., Mulgrave, VIC, Australia) [27 (link),28 (link)]. Resistance to CBP was measured regularly, and CBPR cell lines were seen to be at least two-fold more resistant to CBP than their parental partners through the following experiments.